PeterWesterveltMD

Oncology • Saint Louis, MO

Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Westervelt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Westervelt's full profile

Already have an account?

Office
660 S. Euclid Ave, Box 8007
11 MCC
Saint Louis, MO 63110
Phone+1 314-454-8333

Fax+1 314-454-7551
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1994 - 1999
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1992 - 1994
Washington University in St. Louis School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 2001 - 2026
ME State Medical License 2023 - 2025
MO State Medical License 2006 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant Start of enrollment: 2012 Apr 01
Completed
Phase 1
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
Completed
Phase 2
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Start of enrollment: 2017 Apr 07
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study.
Patrick G Lyons, Vanessa Chen, Tejas C Sekhar, Colleen A McEvoy, Marin H Kollef, Ramaswamy Govindan, Peter Westervelt, Kelly C Vranas, Thomas M Maddox, Elvin H Geng, P...> ;JCO Clinical Cancer Informatics. 2023 Jan 1
22 citations
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Armin Ghobadi, Michael Slade, Hagop Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A Mohammed, Elias Jabbour, Rawan Faramand, Bijal Shah, Frederick Locke, Warren F...> ;Blood. 2022 Nov 17
25 citations
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.
Michael H Kramer, Qiang Zhang, Robert Sprung, Ryan B Day, Petra Erdmann-Gilmore, Yang Li, Ziheng Xu, Nichole M Helton, Daniel R George, Yiling Mi, Peter Westervelt, Ja...> ;Blood. 2022 Sep 29
6 citations
Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.
Andrew J Menssen, Ajay Khanna, Christopher A Miller, Sridhar Nonavinkere Srivatsan, Gue Su Chang, Jin Shao, Joshua Robinson, Michele O'Laughlin, Catrina C Fronick, Rob...> ;Blood Cancer Discovery. 2022 Jul 6
17 citations
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille Abboud, Ravi Vij, Keith Stockerl-Goldstein, Iskra Pusic,...> ;Transplantation and Cellular Therapy. 2022 Aug 1
14 citations
Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells.
Elisabeth R Wilson, Nichole M Helton, Sharon E Heath, Robert S Fulton, Jacqueline E Payton, John S Welch, Matthew J Walter, Peter Westervelt, John F DiPersio, Daniel C...> ;Leukemia. 2022 Apr 1
3 citations
Decitabine salvage for-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.
Francesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, Christopher A Miller, Mary Elizabeth Percival, Geoffrey L Uy, Iskra Pusic, Meagan A Jacoby, Mathew J Christ...> ;Haematologica. 2022 Jul 1
42 citations
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
Melissa M Berrien-Elliott, Jennifer A Foltz, David A Russler-Germain, Carly C Neal, Jennifer Tran, Margery Gang, Pamela Wong, Bryan Fisk, Celia C Cubitt, Nancy D Marin...> ;Science Translational Medicine. 2022 Feb 23
18 citations
Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.
Francesca Ferraro, Christopher A. Miller, Keegan A. Christensen, Nichole M. Helton, Margaret O’Laughlin, Catrina Fronick, Robert S. Fulton, Jessica Kohlschmidt, Ann-Ka...> ;Proceedings of the National Academy of Sciences of the United States of America. 2021 Dec 7
35 citations
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Amanda F. Cashen, Miriam T. Jacobs, Pamela Wong, Mark P. Foster, Ethan McClain, Sweta Desai, Patrick Pence, Sarah Co...> ;Blood. 2021 Nov 19
7 citations
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
Eric Huselton, Michael P. Rettig, Kirsten Campbell, Amanda F. Cashen, John F. DiPersio, Feng Gao, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Mark A. Schroeder, Geoff...> ;Leukemia Research. 2021 Nov 1
6 citations
Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
Allegra A. Petti, Saad M. Khan, Ziheng Xu, Nichole M. Helton, Catrina Fronick, Robert S. Fulton, Sai Mukund Ramakrishnan, Sridhar Nonavinkere Srivatsan, Sharon Heath, ...> ;Blood Cancer Discovery. 2021 Aug 24
55 citations
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplas...
Ryotaro Nakamura, Wael Saber, Michael Martens, Alyssa Ramirez, Bart L. Scott, Betul Oran, Eric S. Leifer, Roni Tamari, Asmita Mishra, Richard T. Maziarz, Joseph P. McG...> ;Journal of Clinical Oncology. 2021 Jun 9
117 citations
Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.
Eric J. Duncavage, Molly C Schroeder, Michele O'Laughlin, R. Wilson, Sandra MacMillan, Andrew Bohannon, Scott Kruchowski, John Garza, Feiyu Du, Andrew E. O. Hughes, Jo...> ;The New England Journal of Medicine. 2021 Mar 10
3 citations
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
Eric Huselton, Michael P. Rettig, Theresa Fletcher, Julie Ritchey, Leah Gehrs, Kyle McFarland, Stephanie Christ, William C. Eades, Kathryn Trinkaus, Rizwan Romee, Shas...> ;Leukemia & Lymphoma. 2021 Jan 19
6 citations
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.
Erica K. Barnell, Kenneth F. Newcomer, Zachary L. Skidmore, Kilannin Krysiak, Sydney R. Anderson, Lukas D. Wartman, Stephen T. Oh, John S. Welch, Keith Stockerl-Goldst...> ;JCO Precision Oncology. 2021 Jan 14
66 citations
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
Melissa M. Berrien-Elliott, Amanda F. Cashen, Celia C. Cubitt, Carly Neal, Pamela Wong, Julia A. Wagner, Mark P. Foster, Timothy Schappe, Sweta Desai, Ethan McClain, M...> ;Cancer Discovery. 2020 Dec 1
IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation.
Peter Westervelt> ;The Lancet. Haematology. 2020 Oct 1
26 citations
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Elizabeth A. Griffiths, Laura M Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter T. Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Zaheer Kidwai, Dwigh...> ;Journal of the National Comprehensive Cancer Network. 2020 Sep 1
13 citations
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
Ramzi Abboud, Ezhilarasi Chendamarai, Michael P. Rettig, Kathryn Trinkaus, Peter A. Riedell, Camille N. Abboud, Armin Ghobadi, Iskra Pusic, Keith Stockerl-Goldstein, M...> ;Haematologica. 2020 Aug 1
1 citations
The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study.
Nahid Rashid, Michael Slade, Ramzi Abboud, Feng Gao, John F. DiPersio, Peter Westervelt, Geoffrey L. Uy, Keith Stockerl-Goldstein, Rizwan Romee, Mark A. Schroeder> ;Transplant International. 2020 Jun 19
Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia.
Peter Westervelt> ;Biology of Blood and Marrow Transplantation. 2020 Mar 1
3 citations
Ruxolitinib for steroid-refractory acute graft-versus-host disease.
Wael Toama, Mark A. Fiala, Iskra Pusic, Peter Westervelt, John F. DiPersio, Mark A. Schroeder> ;Transplant International. 2020 Feb 1
67 citations
Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines
Pamela S. Becker, Elizabeth A. Griffiths, Laura Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter T. Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kalla...> ;Journal of the National Comprehensive Cancer Network. 2020 Jan 1
3 citations
The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Dise...
Joseph Rimando, Michael Slade, John F. DiPersio, Peter Westervelt, Feng Gao, Chang Liu, Rizwan Romee> ;Biology of Blood and Marrow Transplantation. 2020 Jan 1
Join now to see all

Journal Articles

Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution
John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
Bone Marrow Biopsy Needle Type Affects Core Biopsy Specimen Length and Quality and Aspirate Hemodilution
Anjum Hassan, Peter Westervelt, Friederike Kreisel, American Journal of Clinical Pathology
Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published Data
Francesca Ferraro, Peter Westervelt, John F Dipersio, Armin Ghobadi, Leukemia Research
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature
Join now to see all

Abstracts/Posters

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
Peter Westervelt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Peter Westervelt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients
Peter Westervelt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evidence for Complete Mutation Clearance in Normal Karyotype AML Patients with Very Long (> 5 years) Remissions after Chemotherapy Alone
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published DataAugust 2018

Press Mentions

$15 Million Supports Quest for Personalized Leukemia TherapiesAugust 21st, 2019
CX-01 Heparin Derivative Investigated for Older Patients with AMLJune 14th, 2019
$Amphivena Demonstrates at EHA First Human Proof-of-Concept for AMV564 in Relapsed/Refractory AML$
Amphivena Demonstrates at EHA First Human Proof-of-Concept for AMV564 in Relapsed/Refractory AMLJune 15th, 2018
Join now to see all

Grant Support

Clinical DatabaseNational Cancer Institute2008–2012
Sargrastim And Plerixafor Vs. Filgrastim For Allogeneic Stem Cell MobilizationNational Heart, Lung, And Blood Institute2011
Developmental Targeting--Pml Rara Expression In VivoNational Heart, Lung, And Blood Institute2001–2003
Developmental Targeting--Pml Rara Expression In VivoNational Heart, Lung, And Blood Institute1999–2001